MedPage Today on MSN
Parkinson's disease gets new treatment approved
FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...
Texas A&M researchers have developed a novel treatment that protects cells from the toxic buildup linked to Parkinson’s ...
Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...
The Brighterside of News on MSN
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
Once-daily tavapadon offers a new Parkinson’s treatment option, with symptom benefits supported by trials and important ...
After showing meaningful improvements in both the movement and daily lives of people with Parkinson's disease, and new drug ...
Add Yahoo as a preferred source to see more of our stories on Google. Researchers have uncovered how the brain's production of dopamine gets disrupted by "disease-causing mutations" in genes.
Health and Me on MSN
Parkinson’s disease: Women have more motor complications, depression
The study based on clinical data from more than 10,000 Parkinson’s patients showed that men were more likely to experience ...
Scores on a clinical evaluation tool for motor symptoms of Parkinson’s disease stabilized with rexaceract, according to data ...
The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...
Body]I recently came across news about the world's first approval of an iPS cell-derived treatment for Parkinson's disease, ...
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results